FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for BEOVU (brolucizumab) from Novartis Pharmaceuticals Corporation, resulting in an updated label for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• BEOVU (BROLUCIZUMAB)

Snippet

SUPPL AP for BEOVU (BROLUCIZUMAB)